Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04205968 · ClinicalTrials.gov registry record · Phase 2
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
A Phase 2 study of Metastatic Small Intestinal Adenocarcinoma and Stage IV Small Intestinal Adenocarcinoma AJCC v8, sponsored by SWOG Cancer Research Network.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 94
- Enrollment target
- 20
- Study locations
NCT04205968 is a Phase 2 study of Metastatic Small Intestinal Adenocarcinoma and Stage IV Small Intestinal Adenocarcinoma AJCC v8 that is actively recruiting participants, run by SWOG Cancer Research Network. The registered enrollment target is 94 participants. The trial reports 20 study locations across 4 states.
The verdict
NCT04205968, a Phase 2 study of Metastatic Small Intestinal Adenocarcinoma and Stage IV Small Intestinal Adenocarcinoma AJCC v8, is actively recruiting participants, sponsored by SWOG Cancer Research Network.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 94 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase II trial studies how well ramucirumab and paclitaxel or the FOLFIRI regimen (leucovorin calcium, fluorouracil, and irinotecan hydrochloride) work in treating patients with small bowel cancers that have spread extensively to other anatomic sites (advanced) or are no longer responding to treatment (refractory). Ramucirumab is a monoclonal antibody that attaches to and inhibits a molecule called VEGFR-2. This may restrain new blood vessel formation therefore reducing nutrient supply to tumor which may interfere with tumor cell growth and expansion. Drugs used in chemotherapy, such as paclitaxel, leucovorin calcium, fluorouracil, and irinotecan hydrochloride work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving Ramucirumab plus paclitaxel or FOLFIRI, may be helpful in treating advanced or refractory small bowel cancers and may help patients live longer.
Conditions Studied
Interventions
- DRUG Fluorouracil
- DRUG Leucovorin
- DRUG Irinotecan
- DRUG Irinotecan Hydrochloride
- DRUG Leucovorin Calcium
Study Locations (20)
Alaska
- Anchorage Associates in Radiation Medicine - Anchorage
- Anchorage Radiation Therapy Center - Anchorage
- Alaska Breast Care and Surgery LLC - Anchorage
- Alaska Oncology and Hematology LLC - Anchorage
- Alaska Women's Cancer Care - Anchorage
- Anchorage Oncology Centre - Anchorage
- Katmai Oncology Group - Anchorage
- Providence Alaska Medical Center - Anchorage
California
- Kaiser Permanente-Anaheim - Anaheim
- Mission Hope Medical Oncology - Arroyo Grande - Arroyo Grande
- PCR Oncology - Arroyo Grande
- Kaiser Permanente-Baldwin Park - Baldwin Park
- Kaiser Permanente-Bellflower - Bellflower
- Providence Saint Joseph Medical Center/Disney Family Cancer Center - Burbank
Arkansas
- Mercy Hospital Fort Smith - Fort Smith
- CHI Saint Vincent Cancer Center Hot Springs - Hot Springs
- NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro - Jonesboro
- CARTI Cancer Center - Little Rock
Arizona
- Kingman Regional Medical Center - Kingman
- Cancer Center at Saint Joseph's - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2020-06-01 |
| Est. Completion | 2027-08-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04205968
The ClinicalTrials.gov registry entry for NCT04205968 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 94 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Metastatic Small Intestinal Adenocarcinoma appearing as the primary indexed condition, and to 5 interventions - of which Fluorouracil is the first listed.
NCT04205968 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Alaska, California, Arkansas.
Frequently Asked Questions
What is clinical trial NCT04205968 about?
NCT04205968 is a clinical study titled "Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers". This phase II trial studies how well ramucirumab and paclitaxel or the FOLFIRI regimen (leucovorin calcium, fluorouracil, and irinotecan hydrochloride) work in treating patients with small bowel cancers that have spread extensively to other anatomic sites (advanced) or are no longer responding to tr...
What is the current status of trial NCT04205968?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 94 participants. The study started on 2020-06-01. Estimated completion is 2027-08-01.
What conditions does trial NCT04205968 study?
This clinical trial studies the following conditions: Metastatic Small Intestinal Adenocarcinoma, Stage IV Small Intestinal Adenocarcinoma AJCC v8, Stage III Small Intestinal Adenocarcinoma AJCC v8, Stage IIIA Small Intestinal Adenocarcinoma AJCC v8, Stage IIIB Small Intestinal Adenocarcinoma AJCC v8.
What interventions are being tested in trial NCT04205968?
The interventions under investigation include: Fluorouracil (DRUG), Leucovorin (DRUG), Irinotecan (DRUG), Irinotecan Hydrochloride (DRUG), Leucovorin Calcium (DRUG).
Who is sponsoring clinical trial NCT04205968?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04205968 being conducted?
This trial has 20 study locations across Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Small Intestinal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery
ACTIVE NOT RECRUITING · Phase 2
-
Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Metastatic Small Intestinal Adenocarcinoma
All registered trials for this condition
Stage IV Small Intestinal Adenocarcinoma AJCC v8
All registered trials for this condition
Alaska
All trials with a study site in Alaska
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.